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Research into intensive comprehensive aphasia programs (ICAPs) has yet to show that this service delivery model is 
effi cacious, effective, has cost utility, or can be broadly implemented. This article describes a phased research approach 
to the study of ICAPs and sets out a research agenda that considers not only the specifi c issues surrounding ICAPs, but 
also the phase of the research. Current ICAP research is in the early phases, with dosing and outcome measurement as 
prime considerations as well as refi nement of the best treatment protocol. Later phases of ICAP research are outlined, and 
the need for larger scale collaborative funded research is recognized. The need for more rapid translation into practice 
is also acknowledged, and the use of hybrid models of phased research is encouraged within the ICAP research agenda. 
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An intensive comprehensive aphasia pro-gram (ICAP) has been defi ned as a service delivery model that provides a minimum of 
3 hours daily treatment over a period of at least 2 
weeks; uses a variety of different formats including 
individual and group therapy, patient and family 
education, and technological advancements; tar-
gets directly the impairment and the activity and 
participation levels of language and communica-
tion functioning; and has a defi nable start and end 
date, with a cohort of participants entering and 
leaving the program at the same time.1 A survey of 
ICAPs throughout the world found that the major-
ity of the 12 programs have been formed relatively 
recently, with 1 program operating for 20 years.1 
Despite the growing number of ICAPs, there is 
little evidence about their effi cacy, effectiveness, or 
cost-effectiveness. All stakeholders need this evi-
dence. Funding agencies will require evidence to 
make decisions about their investments in aphasia 
rehabilitation. People with aphasia and their fami-
lies should have evidence prior to investing their 
money and time into a program, and speech and 
language pathologists have an ethical obligation 
to provide evidence-based practices. This article 
summarizes current evidence for ICAPs and pro-
poses a research agenda for taking this distinctive 
form of service delivery forward.
ICAPs are a complex intervention for a 
complex problem. Like any intervention, the 
components as well as the whole should be 
informed by evidence. According to defi nitions 
and descriptions of evidence-based practice, 
the sources of evidence include the scientifi c 
literature and the perspectives of the patients and 
clinicians within the context of current health and 
rehabilitation policies and practices.2 This issue 
of Topics in Stroke Rehabilitation provides some 
clinician and consumer perspectives on ICAPs.1,3,4 
Although these perspectives are exceedingly 
valuable sources of information, this article will 
focus on the evaluation of ICAPs using empirical 
experimental methods that will ultimately help 
to determine whether ICAPs promote positive 
outcomes and are cost-effective in routine clinical 
practice.
Generally speaking, the highest level and 
most sought after empirical scientifi c evidence 
that is incorporated into infl uential knowledge 
syntheses such as systematic reviews and clinical 
guidelines is the randomized controlled trial 
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(RCT). The most recent summary of evidence 
of aphasia therapy5 continues to highlight the 
mixed results and poor design of aphasia therapy 
RCTs. Robey and Schultz6 argue that aphasia 
research cannot continue to rely on idiosyncratic 
research methods and that a universal phased 
approach should be used. The phased model 
calls for a series of experiments that use a variety 
of research designs but incorporate the RCT in 
the latter stages. Hence, incremental research 
questions are answered systematically prior to 
the full-scale RCT. This is often not the case 
in aphasia research, which likely contributes 
to the conflicting RCT results in the latest 
Cochrane review.5 The phased approach has 
been applied to complex interventions in health 
care,7 and it has more recently been adapted 
for general neurorehabilitation research.8 In 
addition to arguing that randomized trials to 
investigate effi cacy and (especially) effectiveness 
are appropriately conducted in later phases 
of research, Whyte and colleagues8 forcefully 
advocate the funding and publishing of early-
phase work as essential to development of the 
evidence base.
Although the authors writing on the topic of 
a phased approach to intervention evaluation 
have assigned different names and numbers to 
the phases, the various frameworks correspond 
closely to one another. We will take Whyte and 
colleagues’ presentation as the outline for our 
discussion of a research program for ICAPs. The 
phases are Discovery; Phase I: proof-of-concept, 
safety, and feasibility; Phase II: effi cacy; Phase 
III: effectiveness; and Phase IV: health services 
research – effectiveness beyond the clinic. In 
general, the number of participants in each 
phase increases over time so that the early phases 
include smaller samples whereas the latter phases 
include the largest numbers possible and seek to 
become more defi nitive. It is also worth noting 
that the phased approach can be iterative,7 so if 
the results of a Phase II study are poor, a return to 
Phase I or even Discovery work may be indicated. 
Because progress is not necessarily constrained to 
be linear, work in multiple phases may proceed 
simultaneously. In the remainder of the article, 
we will discuss these phases as they apply to 
ICAPs.
Discovery Phase
In describing the Discovery phase, Whyte 
and colleagues8 emphasized the role of basic 
science and theory in laying the foundation for 
a program of treatment research. In the context 
of clinical aphasiology, basic science may consist 
of research aimed at understanding the cognitive 
or neural substrates of normal and impaired 
communication. It may also consist of efforts to 
elucidate psychological factors or social systems 
that promote or hinder successful adaptation to 
aphasia. With respect to ICAPs in particular, the 
basic neuroscience literature on intensity and 
quantity of neurorehabilitation (reviewed in ref. 
9) as well as the growing literature on intensity in 
aphasia treatment5,10-12 are directly relevant.
Theory and basic research are important 
contributors to Discovery, but we believe that 
clinical experience can also be informative at 
this stage. Many prominent and well-studied 
approaches to the treatment of aphasia and related 
neurogenic communication disorders have their 
genesis in the experience of skilled and well-read 
clinicians as much or more so than in theoretical or 
basic empirical work (see, eg, refs. 13-15). Even in 
cases where there is a primary motivating theory, 
the theory does not necessarily exhaustively 
constrain or inform all the details of the approach 
(see, eg, ref. 16). Also, even though a useful 
theoretical explanation of all important aspects 
of a given treatment is certainly desirable, such 
understanding may be as much the result as it is 
the driver of treatment success, and an exhaustive 
theoretical account should not be mandatory for 
advancing treatment research to Phase I or even 
from Phase I to Phase II work.
Phase I: Proof-of-Concept, 
Safety, and Feasibility
The primary goal of Phase I is to apply the 
new treatment in its initial form and determine 
whether the expected therapeutic effect can be 
detected. According to Whyte and colleagues,8 
work in this phase has other objectives in addition 
to this primary goal, including demonstration 
of the safety and feasibility of the approach, 
selection of outcome measures, estimation of 
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increased fatigue can create mobility safety issues, 
but in our experiences with 3 separate ICAPs, 
these have not posed such a risk to ICAPs that they 
require additional research.
Feasibility and acceptability
There is an evidence gap around the feasibility 
and acceptability of ICAPs. Brady and colleagues5 
suggest that the drop-out rate in intensive trials 
is much higher than in nonintensive trials. 
Certainly most existing ICAPs surveyed1 have 
selection criteria about the endurance of potential 
participants. Most ICAPs are also being offered 
to participants who are at least 6 months post 
onset,1 so the acceptability and feasibility of 
ICAPs in earlier stages has yet to be determined. 
In addition to the required endurance of 
participants with aphasia, therapists must have 
the capacity to provide an ICAP. Feasibility issues 
surrounding appropriate space requirements, 
workforce planning, and simultaneous access to 
multiple computers can be challenging to many 
facilities. Hence, the structural and organizational 
requirements of ICAPs have not been described 
to determine whether ICAPs are a feasible option 
for some service providers. Most existing ICAPs 
are associated with universities rather than health 
care providers, and organizational issues are likely 
to act as a barrier to further uptake by health care 
providers. Thus, demonstration of ICAP feasibility 
from the perspectives of providers and participants 
continues to be an important issue.
Outcome measurement
Selection of outcome measures in aphasia 
rehabilitation research continues to be a vexing 
question. Outcomes measured at all levels of 
the International Classifi cation of Functioning, 
Disability and Health (ICF) and relevant to 
the patient journey may provide important 
information. Whyte and colleagues8 differentiate 
between proximal outcomes that are closely 
related to the proposed treatment and measure 
immediate effects and distal outcomes that are 
more real-world measures and may assess new 
domains of function. They argue that proximal 
outcomes, which for many aphasia treatments 
effect size, and investigation of dosing. Robey17 
and Robey and Schultz6 provide a somewhat more 
elaborate description of this work preliminary to 
effi cacy trials, which they divide into 2 phases. 
The fi rst of these phases is focused on selection 
of a treatment, detection of its effect, and initial 
estimation of its magnitude; and the second phase 
is concerned with refi ning effect size estimates 
and initial specifi cation of the therapy protocol, 
target population, dosing, and outcomes. Given 
the interactive and highly iterative nature of these 
activities, we fi nd it useful to consider them all as 
components of a single phase. Below, we discuss 
some of these components as they apply to ICAPs.
Proof-of-concept
Proof-of-concept requires a demonstration that 
a desired treatment effect can be obtained, at least 
potentially or under some conditions. Design 
considerations for research that is conducted to 
show proof-of-concept permit a fairly high degree 
of fl exibility6,8; weaker designs such as case studies, 
small-group pre and post studies, and retrospective 
investigations may contribute along with stronger 
single-subject and group designs. Although 
recent systematic reviews have been guarded5 or 
equivocal10 on the benefi ts of intensive versus 
nonintensive treatment for aphasia, there is a small 
and growing number of reports documenting 
potential benefi ts of ICAPs.18-21 Many questions 
remain, but we believe that the potential for ICAPs 
to show benefi ts has been demonstrated.
Safety
Animal models suggest that intensive motor 
rehabilitation applied very soon after stroke 
may interfere with recovery.22,23 However, to 
our knowledge, such effects have never been 
demonstrated in humans nor in aphasia treatment 
specifi cally, and the limited evidence to date on the 
timing of aphasia treatment suggests no differences24 
or improved outcomes25 for treatment begun in 
the fi rst 6 months of recovery. Furthermore, as 
with neurorehabilitation in general,8 the history 
of clinical practice in aphasiology suggests that 
research on ICAPs should not be concerned with 
safety as a primary issue. As a secondary issue, 
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treatment. The intervention taken as a whole may 
have sets of proximal and distal outcomes that 
partially overlap. These considerations are further 
complicated by the possibility that there may be 
interactions between ICF levels such that activities 
and participation may impact impairments in 
addition to the reverse.
These considerations aside, it is likely that 
activity or participation outcomes will be of 
ultimate and primary interest to most stakeholders. 
Ideally, these outcomes should be apparent to and 
measurable from the perspectives of the person 
with aphasia and his or her family or social 
community. The last decade has seen an explosion 
of interest in the measurement of patient-reported 
health outcomes across the full range of health 
conditions,27-32 and aphasia is no exception.33-38 
Although these efforts have produced some 
promising results and represent an appropriate 
focus on patients’ perspectives, use of patient-
reported outcomes as primary endpoints in RCTs 
does raise challenges.
One issue concerns the diffi culty of blinding 
patients or surrogate outcome reporters to the 
experimental condition or time point. Blinding is 
included as an item in the Consolidated Standard 
of Reporting Trials (CONSORT) checklist,39,40 
and it is recognized as an important method 
of reducing bias, especially for measures that 
are less objective.41 A potential solution might 
be to develop instruments and protocols that 
would use surrogate outcome reporters who 
could be blinded, recognizing that surrogate 
reports, although valuable, should not be directly 
substituted for patient reports.34
The second issue has been raised in the context 
of patient-reported outcomes but may apply more 
broadly to performance-based and clinician-
reported outcomes. In cases where interventions 
are not expected to raise general functional ability 
(on whatever variable is being measured), but 
rather are intended to affect responses to specifi c 
test items, the size of the treatment effect will 
depend on the number of items included in the 
assessment that are targeted by the intervention.42 
For example, the Communication Outcome after 
Stroke Scale33 includes items about how well the 
respondent can read and write in addition to 
questions about expression and comprehension 
focus on language impairments as opposed to 
activities or participation, are appropriately used 
in Phase I studies where the purpose is to show 
proof-of-concept or to establish the underlying 
mechanism of the effect. For example, if naming 
treatments are applied as a part of an ICAP, tests of 
naming or measures of semantic and phonological 
processing may help to establish whether any 
observed changes have occurred for the reasons 
predicted by underlying theory. This information 
can help to constrain hypotheses about specifi c 
operative components of the treatment and in 
turn lead to refi nement of the approach. When 
socially focused or participation-oriented aphasia 
treatments are applied, the proximal outcomes 
may be more appropriately measured at the 
activity or participation levels of the ICF.
Another reason to choose proximal outcome 
measures is that they can lead to better 
understanding of the underlying treatment 
mechanism. When the underlying mechanism 
is understood, it supports inferences about 
whether the treatment has in fact caused the 
observed changes.26 Conversely, when the results 
of an investigation of more distal outcomes are 
negative, knowledge of the treatment mechanism 
can increase the ability to interpret such negative 
findings. For example, if a treatment with 
established effi cacy or effectiveness for improving 
language function fails to have an impact on a distal 
outcome such as quality of life or return to work, 
the negative fi nding may be due to variables other 
than simple inadequacy of the treatment.8 Even in 
the early phases of ICAP research, both proximal 
and distal outcome measures may be required 
to capture the outcomes of the comprehensive 
program that targets all levels of the ICF.
It is also worth noting that in the context of a 
complex intervention like an ICAP, the distinction 
between proximal and distal outcome measures 
may be less clear. ICAPs, as they are defi ned here, 
target impairment, activity, and participation levels 
of functioning. Thus, whereas individual program 
components may have clearly delineated proximal 
and distal outcomes, it is easy to imagine that a 
distal outcome for one component (eg, improved 
self-reported participation in conversation as 
a function of a naming treatment) may be a 
proximal outcome of a more participation-oriented 
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Clinical trial and error can provide initial 
conclusions about what components work best in 
an ICAP, and ICAPs have been evolving clinically 
for a number of years. Service providers have trialed 
different components and sought the views of 
stakeholders, particularly the service users, about 
the acceptability and perceived effectiveness of the 
individual components. To be defi ned as an ICAP, 
Rose, Cherney, and Worrall1 stated that the program 
should involve the components of individual and 
group therapy, patient and family education, and 
technological advancements.1 Furthermore, the 
targets of intervention should include impairments 
as well as the activity limitations and participation 
restrictions associated with aphasia. The survey 
identifi ed considerable variability between ICAPs 
on these core components and also on additional 
components. For example, even though all 
ICAPs encouraged family involvement, some 
through observation and others through direct 
participation, not all programs included sessions 
specifi cally for family members. Also, the range 
of staff who are involved with the surveyed ICAPs 
(social work, music therapists, recreation offi cers, 
other allied health, psychology, volunteers) 
suggested that the programs may include other 
components as well.
The mix of components that make an ICAP 
“comprehensive” is potentially a response to 
documented unmet need in patient and family 
education46,47 and group therapy.48 Stroke 
rehabilitation guidelines in many countries 
have driven the inclusion of these components 
into practice. For example, the Australian 
Stroke Rehabilitation Guidelines49 recommend 
that “all stroke survivors and their families/
carers should be offered information tailored to 
meet their needs using relevant language and 
communication formats” (Level A evidence). 
There are similar statements regarding the other 
components: “Group therapy and conversation 
groups can be used for people with aphasia and 
should be available in the longer term for those 
with chronic and persisting aphasia” (Level C); 
“Interventions should be individually tailored 
but can include delivery of therapy programs via 
computer” (Level C). Although more recently 
published systematic reviews48,50 have upgraded 
the level of evidence in some areas, there is 
in conversation and the impact of speech and 
language problems on family and social life. If an 
intervention targeted at improving participation 
in family conversation is provided, and this 
intervention does not have goals related to reading 
and writing, the inclusion of reading and writing 
items in the outcome assessment may dilute 
the treatment effect. Conversely, if a treatment 
is expected to improve the underlying language 
impairment in such a way that it manifests as a 
general improvement in communication ability 
that impacts responses to all items equally (perhaps 
a heroic assumption), the treatment effect will be 
independent of the particular items administered 
and it may be benefi cial to include as many items 
as possible to maximize reliability. Even with 
impairment-focused aphasia treatments, item-
specifi c and domain-specifi c treatment effects are 
common, and researchers have traditionally dealt 
with this by assessing treated and untreated items 
and tasks separately. Users of patient-reported 
outcomes should consider the possibility of item-
specifi c treatment effects and either demonstrate 
that they are absent or take steps to minimize 
or account for the potential bias on effect size 
estimates.
Specifi cation of the treatment protocol
One of the central sources of tension in the 
evaluation of ICAPs will likely be specifi cation of 
the protocol. On one hand, failure to defi ne and 
understand the components of a complex health 
intervention in the early phases of work can lead 
to problems in later phases.7 On the other hand, 
relying on traditional RCTs and delaying them 
until the research necessary to fully characterize 
the effects of the component treatments delivered 
in an ICAP (and their potential interactions) has 
been completed may deny participants, clinicians, 
policymakers, and other stakeholders needed 
evidence for decades to come.43 We suggest that 
this confl ict may be resolved at least in part by 
taking the view that the phases outlined here are 
iterative7 and may at times proceed concurrently 
with one another. Our position is also informed by 
the distinction between explanatory and pragmatic 
trials,44,45 discussed below under Phase III, and a 
recognition that both are necessary.
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To establish the optimal intensity of an 
intervention, clinicians must consider the 
number of times a teaching episode occurs per 
session. A teaching episode contains the unique 
combination of active ingredients that is essential 
to the therapeutic process.58 For example, in a 
word retrieval task, a single teaching episode 
may include the sequence of steps given to cue a 
naming response; different outcomes may occur 
if the number of target words varies or if there are 
differences in the number of times each target is 
practiced (eg, 20 target words practiced 3 times vs 
15 target words practiced 4 times). Later studies 
should investigate how these variations in dose (ie, 
teaching episodes) affect ICAP outcomes.
There are many factors that may infl uence the 
responsiveness of the person with aphasia to a 
specifi c dose of treatment; despite the selection 
of a homogeneous group of subjects, outcomes 
may differ. Therefore, for each participant in 
the ICAP, it may be useful to establish a dose-
response relationship that describes the change in 
a specifi ed outcome caused by differing levels of 
exposure (or doses). This would require frequent 
measurement of performance on specifi c “probes” 
or behaviors of interest. The dose-response curve 
is the graphic representation of the relationship 
between treatment amount or intensity (x axis) 
and the response or change in performance (y 
axis) on an outcome. It can illustrate the graded 
responses of the individual to varying amounts 
of treatment. Examination of the graph can show 
the threshold at which a minimal detectable 
response occurs and how much treatment is 
required to obtain a maximal response. The dose-
response curves of participants could be analyzed 
statistically to provide information regarding 
responsiveness of subgroups of participants with 
aphasia to accumulating amounts and intensities 
of treatment.
Phase II: Effi cacy
The goal of Phase II is to establish treatment 
effi cacy. Robey and Schulz6 provide a helpful 
defi nition of the term effi cacy and point out that 
it has 3 main features. First, inferences regarding 
effi cacy are made at the level of populations, not 
individuals. Second, effi cacy research requires 
still little evidence for the superior effi cacy or 
effectiveness of particular treatment approaches 
over others.5,51,52 Clearly, the relative potency of 
different potential ICAP components in relation 
to patient characteristics and specifi c outcomes 
should be the object of continued empirical 
study. Is family and patient education the vital 
component for long-term maintenance of gains? 
Are gains in spoken output only achieved through 
impairment-focused interventions or is practice 
in real-life situations necessary? Are the greatest 
participation gains made through group therapy? 
What cognitive, linguistic, lesion, or psychosocial 
characteristics moderate treatment effects? The 
gaps in this phase include better evidence for the 
components themselves as well as comparative 
studies of the components typically included in 
an ICAP.
Dosage
There has been considerable attention about the 
intensity requirement for aphasia therapy.5,10,11,53 
This is one of the catalysts for the development 
of ICAPs and why “intensive” was included in 
the ICAP acronym. A research agenda for ICAPs 
includes research particularly addressing the 
intensity of treatment.
Evidence suggests that intensive therapy results 
in positive outcomes, although variations in patient 
characteristics such as aphasia type and severity, 
treatment type, and outcome measures complicate 
comparisons across studies. Some studies have 
examined a single therapy at a high intensity,54,55 
and others have compared 2 treatments given at 
the same high intensity.56,57 Some treatment studies 
have directly compared conditions of higher 
and lower intensity treatment for aphasia.11 Yet, 
optimal intensity has not been established for even 
one type of aphasia treatment.
Determining the optimal intensity of a behavioral 
intervention is complex and may need to be 
investigated iteratively.8 For the ICAP, initial 
studies are needed that systematically contrast 
parameters such as session duration (eg, 6 hours 
a day), session frequency (eg, 5 days a week), 
and total duration (eg, 4 weeks), while keeping 
constant elements of the dose form (eg, type of 
treatment and treatment tasks).
 Research Agenda for ICAPs 415
a user self-pay environment, where funds are 
available to pay for each participant’s treatment 
as well as for the administration of the research 
protocol. Many ICAPs are user self-pay, hence 
there is a need to obtain large-scale research 
funding to take ICAP evaluation to the stage of an 
effi cacy trial.
Another issue to be considered in designing an 
RCT for an ICAP is the potential need for cluster 
randomization. Given that ICAPs typically involve 
cohorts of patients who begin and end treatment at 
the same time, it may be appropriate to randomize 
participants at the level of these cohorts rather 
than at the level of the individual participant. 
Cluster randomization has often been used to 
guard against experimental contamination caused 
by contact between participants in the active 
treatment and control arms of an RCT.60-62 Such 
contact would be likely to occur in the context 
of an ICAP if participants in both the active and 
control groups were being seen at the same facility 
concurrently. On a related but distinct issue, 
the typical structure of ICAPs also suggests that 
multilevel statistical models in which participants 
are nested within cohorts should be considered for 
data analysis.63
Phase III: Effectiveness
In contrast to effi cacy, effectiveness refers to 
inferences made when treatments are studied 
under conditions consistent with typical clinical 
practice.6,8,64 Effectiveness studies are concerned 
with the generalizability of the treatment and are 
usually a step closer to the real world of health 
care. The treatment is administered to larger 
numbers of heterogeneous patients in different 
treatment centers by different clinicians who vary 
in their level of expertise and must deal with the 
time constraints and competing demands of the 
clinic.
As in Phase II, RCTs are the preferred design. 
However, different clinical environments may 
infl uence the structure of the ICAP (eg, number of 
hours per day, number of weeks) or the availability 
of some of its components (eg, computer-based 
treatment, family education). Furthermore, for 
a Phase III effectiveness trial, specifi cation of 
treatment procedures and thus fi delity of treatment 
that both the treatment and the population be 
focused and well defi ned. Third, the treatment 
must be applied under optimal conditions, 
that is, by well-trained clinicians, to carefully 
selected patients, with optimal facilities, and 
with outcomes evaluated by the most appropriate 
measures. Effi cacy studies often use a parallel 
group design in which participants are randomly 
assigned to either the experimental intervention 
group or control group. Although the CONSORT 
statements are intended to provide guidance 
for the reporting rather than the design and 
conduct of clinical trials, the items included in the 
CONSORT checklists are quality markers and may 
thus help investigators to introduce as much rigor 
as possible into the work.39,40 A well-designed and 
conducted RCT should determine whether the 
intervention works or not.
There are no RCTs of ICAPs as yet. An RCT 
would require a selection of “ideal” participants 
who are randomly allocated to an ICAP or a 
control group. Control groups are often diffi cult 
to design in ICAPs, because the participants are 
usually aware of the therapy they are receiving 
and it is diffi cult to fi nd a control condition of 
similar dosage and intensity that does not have an 
impact on aphasia outcomes.59 Given that ICAPs 
are of relatively short duration, wait-list control 
groups, in which participants eventually receive 
the intervention, may be an ethical option.59 A 
no-treatment condition also does not control for 
the effect of the contact time between client and 
therapist or the Hawthorne effect that occurs when 
a client is expecting change. A placebo analogue 
or attention control group that controls for a 
similar dosage of contact would be desirable.59 
Such attention control groups have typically 
undertaken activities that should not have an 
impact on the outcome of interest, for example, a 
hand task when lower limb mobility is the focus 
of intervention. Communication is a feature of 
most interpersonal contact and is often thought 
to have an impact on outcomes generally, so it 
is challenging to design attention control groups 
that do not involve communication. An additional 
challenge is making the control task as interesting 
as the experimental task so that participants 
do not drop out of the study. An effi cacy RCT 
is only possible in a research environment, not 
416 TOPICS IN STROKE REHABILITATION/SEPT-OCT 2013
trials emphasize external validity and generate 
answers about effectiveness.5,67 In some cases, 
explanatory trials are appropriately conducted 
before pragmatic trials, but in others the reverse 
may be true.66
To the ethical issue raised by Robey,17 we would 
add the following observations. First, services 
may be provided with reasonable expectation 
of benefi t based on evidence other than effi cacy 
established by one or more RCTs. Second, 
delays in research that is relevant to the needs 
of patients and practitioners can be considered 
a risk to research participants, patients, and to 
the public.43 Thus, we agree that the negative 
findings with limited interpretability arising 
from an expensive effectiveness trial are a risk 
that should be mitigated against. However, 
we also believe that it may be appropriate in 
some cases to address questions of effectiveness 
without fi rst defi nitively establishing effi cacy 
or to consider ways of integrating questions of 
effi cacy, effectiveness, and implementation into 
the same trial.68,69
Phase IV: Health services research
The fi nal phase of research aims to determine 
whether change is required in health service 
delivery or policy. Questions surrounding the cost-
effectiveness and cost benefi t of the intervention 
as well as comparison trials to determine whether 
other current interventions have better or 
worse cost-effectiveness are studied. There is an 
increasing demand for implementation studies to 
determine the most effective ways to implement 
the intervention into practice.
Rehabilitation is expensive, and an intensive 
specialized program such as an ICAP incurs 
substantial costs. Do these translate into benefi ts 
for the participants and society in general? An 
economic analysis will evaluate the relative 
resource use and costs and, thereby, the cost-
effectiveness of an ICAP. Generally, cost data (cost 
of all key services and resources used during the 
ICAP) are collected during the RCT, and costs are 
then displayed against their benefi ts as measured 
by units of improvement on the relevant outcome 
measure. For example, this calculation may 
pose diffi culties because of the heterogeneity of the 
subjects. This contrasts with a Phase II effi cacy 
trial, where fi delity of treatment is accomplished, 
in part, by the standardization and manualization 
of the treatment procedures together with 
extensive training of the clinicians and periodic 
monitoring throughout the trial to ensure that 
all participants are receiving the same treatment. 
There are many aphasia treatments to choose 
from, and it may not be feasible to standardize the 
components of the ICAP and the exact treatments 
so that the ICAP can be replicated across sites for 
a heterogeneous group of subjects with different 
strengths and defi cits. Conducting a meta-analysis 
of the outcomes from different ICAPs may be one 
solution to assessing effectiveness when there 
is lack of uniformity of ICAPs across different 
settings.8
According to Whyte and colleagues,8 
improvement in Phase III is measured by outcomes 
that are closely related to the target of treatment as 
well as outcomes that assess important but more 
distal functional areas. As previously discussed, the 
focus on 2 distinct outcome domains may be less 
relevant to ICAPs given the comprehensive nature 
of the ICAP and its inclusion of treatments that 
target both impairment and activity/participation. 
Both outcome domains would have been 
addressed in Phase II.
The literature on phased models for clinical 
outcome research in aphasia has held that effi cacy 
must be established before effectiveness can be 
investigated.6,17 Robey,17 on the assumption that 
subjects in effectiveness trials are likely to be 
clients of clinical service providers, suggested that 
establishing effi cacy before studying effectiveness 
satisfi es the ethical obligation to provide services 
only when benefi t can reasonably be expected. 
However, it has been observed that the transition 
between effi cacy trials and effectiveness trials 
lacks a clear boundary,8,65 and the view that 
effi cacy must be established fi rst in all cases 
is not universally held.44,65,66 The idea of an 
explanatory-to-pragmatic continuum in clinical 
outcomes research is helpful in considering 
these questions.44,45,66 Briefly, explanatory 
trials emphasize internal validity and provide 
inferences about efficacy, whereas pragmatic 
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integration of ICAP therapy into clinical practice, 
consideration of the implementation process is 
critical. Implementation research identifi es ways 
in which the context or environment affects 
implementation, provides information on how 
to refi ne or adapt the intervention, and provides 
critical information for future replication and 
dissemination. Hybrid designs that simultaneously 
assess the effectiveness of an intervention and its 
potential for implementation have been proposed 
and may be appropriate for future investigation of 
the ICAP.68
Conclusion
A considerable amount of research on the 
effects and value of ICAPs remains to be done. 
Greater attention to earlier phases of research 
may mean that subsequent RCTs are more likely 
to show benefi t. Hence, there is a need to refi ne 
the intervention, the responders, and the outcome 
measures so that effi cacy and effectiveness trials 
are as well controlled as possible. There is a clear 
need for more Phase I research on ICAPs. Also, 
multisite studies and large-scale funding will likely 
be required for all subsequent phases, making 
collaboration across ICAP sites and researchers 
essential.
ICAP researchers may need to consider hybrid 
models to speed up the process of phased 
research. There is now a need to collect data 
about costs and begin to measure the value of 
ICAPs in terms of willingness to pay per unit of 
improvement. There is also need to examine the 
barriers and facilitators to implementing ICAPs. 
If at the end of this research effort, ICAPs are 
shown to be cost-effective and have cost utility, 
then they can be implemented so that all people 
with aphasia can access an ICAP within their local 
health service.
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allow researchers to indicate the dollar amount 
required per unit of improvement on the chosen 
outcome measure. This is useful to persons who 
have aphasia, but the cost-effectiveness of ICAPs 
cannot be compared to health care interventions 
for other conditions. Hence, the broader measure 
of quality-adjusted life years (QALYs) is used. This 
introduces the concept of cost utility analyses. 
Even though an ICAP may offer value for money, 
unless people value the benefi t that it may bring 
(and are willing to pay for it), then health service 
providers may be reluctant to choose an ICAP, for 
example, over another health or rehabilitation 
program.
Comparative studies may occur at this stage 
or earlier. Comparisons between different 
interventions may be studied, because they 
may either be less expensive or convey more 
benefi t, thereby altering the cost-effectiveness 
ratio. A potential comparison treatment may be 
a noncomprehensive treatment such as intensive 
impairment-based therapy (eg, constraint-
induced aphasia therapy [CIAT]) that has 
high levels of evidence and is known to be 
effective. However, a comparable dosage of 
noncomprehensive therapy, such as 4 hours a 
day of CIAT, may not be tolerated as well by 
both clients and therapists. Another comparison 
would be with a nonintensive but comprehensive 
treatment. Participants with aphasia who are 
receiving standard care may also be an appropriate 
comparison group, because a primary question 
about ICAPs must be whether they produce 
better outcomes to the standard care provided in 
typical clinical practice.
Finally, there is a need to translate strong 
evidence into practice. A growing concern is the 
gap between research and practice and the slow 
rate at which research results are translated into 
clinical practice.43,69 For an RCT, it may take more 
than 7 years from grant submission to publication 
and as much as 17 years from initiation of a 
concept to implementation into practice.43 Indeed, 
there is a relative paucity of effectiveness trials and 
health services research in relation to the number 
of effi cacy trials of behavioral interventions,69 a 
situation that is also clearly present in the area 
of aphasia research. To facilitate more rapid 
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